Cue Biopharma (NASDAQ:CUE) Downgraded by ValuEngine to “Sell”

ValuEngine lowered shares of Cue Biopharma (NASDAQ:CUE) from a hold rating to a sell rating in a research report released on Wednesday morning, ValuEngine reports.

Several other analysts have also recently commented on CUE. Zacks Investment Research cut Cue Biopharma from a buy rating to a hold rating in a report on Tuesday, October 8th. Robert W. Baird initiated coverage on Cue Biopharma in a report on Thursday, July 25th. They issued an outperform rating and a $13.00 target price on the stock.

CUE stock opened at $8.80 on Wednesday. The stock has a market cap of $201.89 million, a price-to-earnings ratio of -4.54 and a beta of 1.21. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.17 and a quick ratio of 3.17. The company has a fifty day moving average price of $8.11 and a two-hundred day moving average price of $8.06. Cue Biopharma has a one year low of $4.16 and a one year high of $9.94.

A number of hedge funds have recently made changes to their positions in the stock. Sigma Planning Corp boosted its holdings in Cue Biopharma by 25.9% in the third quarter. Sigma Planning Corp now owns 60,210 shares of the company’s stock valued at $508,000 after acquiring an additional 12,405 shares during the last quarter. Russell Investments Group Ltd. bought a new position in shares of Cue Biopharma during the 3rd quarter worth approximately $67,000. Strs Ohio boosted its holdings in shares of Cue Biopharma by 88.0% during the 3rd quarter. Strs Ohio now owns 28,200 shares of the company’s stock worth $237,000 after buying an additional 13,200 shares in the last quarter. Rock Creek Group LP bought a new position in shares of Cue Biopharma during the 2nd quarter worth approximately $447,000. Finally, Vanguard Group Inc. boosted its holdings in shares of Cue Biopharma by 33.8% during the 2nd quarter. Vanguard Group Inc. now owns 612,151 shares of the company’s stock worth $5,504,000 after buying an additional 154,639 shares in the last quarter. Institutional investors and hedge funds own 20.09% of the company’s stock.

About Cue Biopharma

Cue Biopharma, Inc, a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic designed to target and activate antigen-specific T cells for human papilloma virus driven cancers.

Further Reading: Why are gap-down stocks important?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.